Search Results
Your search for ,are matches 22257 pages
Showing 251 - 300Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings
Virtual sustained counseling and nicotine replacement therapy led to an almost doubling of 6-month smoking quit rates compared with standard care for patients facing a recent cancer diagnosis, according to findings from the randomized controlled ECOG-ACRIN EAQ171CD trial from the National Cancer...
Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer
New results from an Alliance Foundation Trials (AFT) study reveal that a simple weekly electronic symptom check-in with the care team significantly improves the quality of life for individuals undergoing treatment for advanced cancer. Researchers found that the biggest improvements were seen among...
ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance resulted in more toxicity with no survival benefit from continuing treatment until disease progression compared with stopping after 2 years. Results from the...
KRAS G12D–Mutated Metastatic Pancreatic Cancer: Zoldonrasib Plus Chemotherapy
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented at the ESMO Gastrointestinal Cancers Congress 2026 (Abstract...
Over 50 Million Americans Live in Counties Without a Radiation Oncology Clinic
More than 50 million Americans live in counties without a radiation oncology practice site and millions more are at risk, according to a new study published by Yu et al in the International Journal of Radiation Oncology • Biology • Physics (Red Journal). The national analysis found that from 2018...
American Cancer Society Reports Latest Global Cancer Statistics
New findings in a report led by the American Cancer Society (ACS) reveal an urgent picture of a growing global cancer burden and underscore the life-saving potential of stronger prevention and equitable access to care. According to Global Cancer Statistics, 2026, nearly 21 million people were...
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases
In a phase III trial (CAIRO6) reported in The Lancet Oncology, Rovers et al found that perioperative systemic therapy was not associated with significant improvement in overall survival vs surgery alone in patients with resectable peritoneal-only metastases of colorectal adenocarcinoma. Study...
Shared Risk Factors Between Breast Cancer and Atrial Fibrillation/Flutter
Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women aged 55 years and older in multiple regions of the world, according to new research published by Zhang et al in the Journal of the American Heart Association. Breast cancer and atrial fibrillation—also...
FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer
On July 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), each in combination with the NECTIN4-directed antibody-drug conjugate enfortumab vedotin-ejfv (Padcev), as neoadjuvant...
FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
On July 9, the U.S. Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications. The specific indications approved for isatuximab are: In combination with pomalidomide and dexamethasone...
Oral Cancer: Novel Diagnostic Test Demonstrates High Accuracy
A noninvasive oral brush biopsy test adapted from a molecular assay was able to quickly distinguish oral squamous cell carcinoma from other oral disorders with high accuracy, according to results from a large diagnostic case-control study published in Biomarker Research. “Oral cancer survival is...
In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types
Between 2015 and 2022, men were more likely than women to be diagnosed with regional and/or distant stages of 20 nonreproductive solid cancer types in the United States, according to a study published by Maclin et al in Cancer Epidemiology, Biomarkers & Prevention. The study’s findings may...
Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma
Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published in Nature Communications. “Targeted therapy works by shutting down the main signal driving...
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia called blastic plasmacytoid dendritic cell neoplasm (BPDCN) may eventually develop resistance to tagraxofusp-ezrs, the first U.S. Food and Drug Administration–approved...
Zenocutuzumab Shows Durable Antitumor Activity in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab induced clinically meaningful antitumor activity and showed a favorable safety profile in patients with advanced NRG1-positive cholangiocarcinoma, according to findings from the phase II eNRGy trial published in the Journal of Clinical Oncology. “Second-line chemotherapy is only...
Early Research Explores How Fatty Liver Disease May Affect Liver Metastasis Among Patients With Colorectal Cancer
Researchers have uncovered how fatty liver disease can fuel the most aggressive form of metastatic colorectal cancer. The findings, published by Peng-Winkler et al in Nature, not only explain why some patients face poorer outcomes but also highlight how metabolic conditions such as fatty liver...
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
In the long-term follow-up to a phase II study published in The New England Journal of Medicine, Ruella et al found that a single infusion of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 (now called tisagenlecleucel) produced decade-long remissions in a subset of patients ...
Study Uncovers How Obesity Influences Molecular Pathways in Breast Cancer Progression
A novel study has found that obesity is associated with a distinct molecular program driving the transition from early-stage, premalignant breast lesions to invasive breast cancer. Rather than simply showing increased activation of classical invasive pathways, tumors from patients with obesity...
Previously Untreated Advanced NSCLC With High PD-L1 Expression: PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy?
In a meta-analysis reported in JAMA Oncology, Di Federico et al found that the addition of first-line platinum-based chemotherapy to PD-1/-L1 inhibition was associated with improved outcomes in patients with advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression. Study Details The...
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, has announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research...
AACR Statement and Call to Action Concerning OMB Proposal
On June 30, the American Association for Cancer Research (AACR) issued the following statement: The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal...
FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant
On June 30, the U.S. Food and Drug Administration (FDA) approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative...
Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs
A novel bleeding risk score provides clinically relevant stratification for major bleeding risk in patients with cancer-associated venous thromboembolism (VTE) who received direct oral anticoagulant (DOAC) therapy, according to findings published in JACC: CardioOncology. “The ONCO-DOAC BLEED score ...
ASCO Remembers Karnofsky Award Recipient Maura L. Gillison, MD, PhD, Pioneer in HPV-Associated Cancers
Reprinted with permission from ASCO Connection, June 26, 2026. ASCO joins the oncology community in mourning the loss of Maura L. Gillison, MD, PhD. As a medical oncologist specializing in thoracic/head and neck cancers, and as a molecular epidemiologist, Dr. Gillison definitively characterized the ...
Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy
Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,...
I Miss My Life
Mr. A was a young professional who walked into my outpatient clinic one morning with his mother by his side. He wore a warm smile, yet there was a quiet heaviness beneath it. A few months earlier, he had been diagnosed with a malignant brain tumor and had undergone primary treatment. He was now...
Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal
Most patients who receive a cancer diagnosis still prefer to learn of the diagnosis from their doctors rather than from reports uploaded to their online health portal, according to findings of a survey conducted at the University of Texas Southwestern Medical Center. Findings were published as a...
Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer
In a meta-analysis reported in The Lancet Oncology, Zhu et al identified treatment-related adverse events associated with the use of CD3-based T-cell–engaging bispecific antibodies in patients with hematologic or solid cancers. Study Details The analysis included studies of CD3-based...
Fertility Preservation Access Remains ‘Limited and Unequal’ for Many Girls and Young Women With Cancer
A new Columbia University School of Nursing systematic review published by Algave et al in the journal Cancer reveals access to fertility preservation care remains limited and unequal for girls and young women with cancer. Each year, more than 85,000 adolescents and young adults (AYAs)—individuals...
AACR Cancer Disparities Progress Report: Trends Show Mortality Rates Improve But Inequity in Care Remains
On June 24, the American Association for Cancer Research (AACR) released its Cancer Disparities Progress Report 2026.1 As in past years, the report features the unprecedented progress being made against cancer, including the ongoing decline in cancer death rates, which have decreased by 35% since...
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new...
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...
Update to ASCO Guideline on Advanced NSCLC Without Driver Alterations Adds Retifanlimab to Treatment Options
ASCO has issued an update to its living guideline on systemic therapies for patients with stage IV NSCLC without driver alterations.1 The update, which includes a new recommendation regarding the PD-1 inhibitor retifanlimab-dlwr and chemotherapy, follows a recent full update to the guideline...
Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer
Two investigational KRAS inhibitors showed activity in previously treated KRAS-mutant non–small cell lung cancer (NSCLC), according to findings presented during the Clinical Trials Plenary Session at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. Elisrasib was ...
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for two indications in adults with triple-negative breast cancer (TNBC). The first indication, supported by data from ASCENT-03, is for sacituzumab govitecan as a ...
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the...
SENOMAC Trial: Omission of Completion Axillary Dissection Is Oncologically Safe in Expanded Breast Cancer Population
The international non-inferiority SENOMAC trial has confirmed that omitting completion axillary lymph node dissection (ALND) is oncologically safe (ie, a less intensive approach does not compromise outcomes) and substantially reduces patient-reported arm morbidity in patients with one or two...
TAPUR Marks a Decade of Innovation
In 2013, during the ASCO Annual Meeting, Richard L. Schilsky, MD, FACP, FSCT, FASCO, then ASCO’s Chief Medical Officer, presented a bold clinical trial concept during an educational session on the challenges of delivering precision medicine services in an oncology community care setting. The idea...
Abemaciclib Reduces Disease Progression, Death in Rare, Aggressive Soft-Tissue Sarcoma
In the treatment of advanced dedifferentiated liposarcoma, a rare and aggressive soft-tissue sarcoma, the CDK4/6 inhibitor abemaciclib significantly reduced the risk of disease progression or death by 62% as compared with placebo in the randomized phase III SARC041 study.1 Mark Dickson, MD, of...
Wearable Devices May Help Detect CRS Earlier in Patients With Myeloma Receiving CAR T-Cell Therapy
Researchers have found that wearable devices may help clinicians detect cytokine-release syndrome—a common and potentially serious side effect of chimeric antigen receptor (CAR) T-cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma. The findings,...
Case 2: Patient With Double-Refractory High-Risk CLL
This is Part 2 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss treatment...
Chinese Study of HER2-Targeted Combination in Neoadjuvant Therapy for Locally Advanced Breast Cancer
A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the...
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a press briefing ahead of the 2026 ASCO Breakthrough Meeting,1...
Multi-Cancer Early Detection Test Evaluated in Real-World Asian Cohort
A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical practice, including cancers for which no standard screening programs currently exist. The research was ...
AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma
Researchers have developed and validated an artificial intelligence (AI)‒assisted volumetric response criteria for assessing response in pleural mesothelioma. The AI-backed criteria outperformed both humans and standard international Response Evaluation Criteria in Solid Tumors (RECIST) criteria,...
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
The American Gastroenterological Association (AGA) recently reported that among expanding options for colorectal cancer screening, colonoscopy remains the AGA's top recommendation. In a business announcement, the organization noted that new screening guidance has alerted patients and primary care...
FDA Warns of Ongoing Breast Biopsy Needle Shortage
The U.S. Food and Drug Administration (FDA) issued notice of supply chain interruptions for stereotactic breast biopsy needles due to recent supplier issues. Disruption in biopsy needle manufacturing is expected to impact patient care and could require adjustments for the management of patients...
St. Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally
St. Jude Children's Research Hospital has announced that they have been redesignated as a World Health Organization (WHO) Collaborating Centre for Childhood Cancer. The new designation recognizes the work of St. Jude to support WHO in integrating childhood cancer into national cancer control plans; ...
Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy
Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, according to study findings published in Immunity. Study Methods and Key Findings Researchers analyzed two...
Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab
Patients with multiple myeloma who received a new immunotherapy combination had significantly longer progression-free survival and showed early signs of improved overall survival, according to findings from the phase III MonumenTAL-3 trial. Peter M. Voorhees, MD, Professor of Medicine at Wake...
